Wells Fargo Maintains Overweight on Axsome Therapeutics, Raises Price Target to $256

Benzinga Newsdesk www.benzinga.com Positive 80.6%

Neg 0% Neu 0% Pos 80.6%

Wells Fargo analyst Benjamin Burnett maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and raises the price target from $255 to $256.